Phase I Trial of Vandetanib (ZD6474, Zactima) and Fulvestrant (Faslodex) as Third-Line Treatment of Advanced Non-Small Cell Lung Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2015
At a glance
- Drugs Fulvestrant (Primary) ; Vandetanib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 09 Jul 2015 Status changed from discontinued to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 10 Mar 2010 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Nov 2009 New trial record